SCHEMBL6147153

SCHEMBL6147153

CCCCO[C@H](C(=O)Oc1ccc(C(=O)OCc2ccccc2)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.46
CYP26A1 O43174 2/20 0.46
CYP26B1 Q9NR63 1/20 0.46
RXRA P19793 3/20 0.44
HNF4A P41235 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RXRB P28702 1/20 0.42
RARB P10826 8/20 0.42
RARA P10276 7/20 0.42
RARG P13631 6/20 0.42
LMNA P02545 1/20 0.40
KMT2A Q03164 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6143991 1.00 CYP3A4 (0.46) CYP3A4CYP26A1CYP26B1RXRAHNF4A
SCHEMBL6147485 0.87 CYP26A1 (0.60) CYP3A4CYP26A1CYP26B1RXRAHNF4A
SCHEMBL6144495 0.87 CYP26A1 (0.60) CYP3A4CYP26A1CYP26B1RXRAHNF4A
SCHEMBL6144036 0.87 CYP26A1 (0.60) CYP3A4CYP26A1CYP26B1RXRAHNF4A
SCHEMBL6144485 0.86 CYP3A4 (0.43) CYP3A4CYP26A1CYP26B1RXRAHNF4A
SCHEMBL6144815 0.85 CYP3A4 (0.46) CYP3A4CYP26A1CYP26B1RXRATDP1
SCHEMBL6144812 0.85 CYP3A4 (0.46) CYP3A4CYP26A1CYP26B1RXRATDP1
SCHEMBL6146814 0.83 CYP26A1 (0.60) CYP3A4CYP26A1CYP26B1RXRAHNF4A
SCHEMBL6148024 0.83 CYP3A4 (0.47) CYP3A4CYP26A1CYP26B1RXRATDP1
SCHEMBL6147677 0.82 CYP3A4 (0.43) CYP3A4CYP26A1CYP26B1RXRATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB CYP3A4 2129/4885CYP26A1 474/4885CYP26B1 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.